Medpace(US:MEDP)2025-04-22 18:39Q1 2025 Financial Performance - Revenue increased to $558.6 million, a 9.3% increase compared to $511.0 million in Q1 2024 [13, 21] - Net new business awards decreased by 18.8% to $500.0 million, compared to $615.6 million in Q1 2024 [13] - EBITDA increased by 2.6% to $118.6 million, compared to $115.7 million in Q1 2024 [21] - Net income increased by 11.7% to $114.6 million, compared to $102.6 million in Q1 2024 [21] - Net income per diluted share increased by 14.7% to $3.67, compared to $3.20 in Q1 2024 [21] Backlog and Book-to-Bill - Ending backlog decreased slightly by 2.1% to $2,846.0 million, compared to $2,907.1 million in Q1 2024 [13] - Net book-to-bill ratio was 0.90, compared to 1.20 in Q1 2024 [13] - Backlog conversion rate increased to 19.2%, compared to 18.2% in Q1 2024 [13] Cash Flow and Guidance - Free cash flow was $115.8 million, while it was $147.2 million in Q1 2024 [42] - Full year 2025 revenue guidance is $2,140.0 million to $2,240.0 million, representing a 1.5% to 6.2% growth rate [29, 44] - Full year 2025 EBITDA guidance is $462.0 million to $492.0 million, representing a (3.8)% to 2.5% growth rate [29, 44]